Exelixis
EXEL
#1651
Rank
โ‚น1.284 T
Marketcap
โ‚น5,183
Share price
0.35%
Change (1 day)
58.41%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น280.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น296.91. In 2025 the company made an earnings per share (EPS) of โ‚น274.15.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น280.562.34%
2025โ‚น274.15
2023โ‚น61.9714.61%
2022โ‚น54.07-22.97%
2021โ‚น70.20100%
2020โ‚น35.10-65.09%
2019โ‚น100.55-53.91%
2018โ‚น218.18333.96%
2017โ‚น50.28-260.61%
2016-โ‚น31.30-58.75%
2015-โ‚น75.89-42.45%
2014-โ‚น131.865.3%
2013-โ‚น125.22

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น828.57 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น124.27-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,374 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น242.81-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น339.11 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น337.70 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น368.66 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น2,258-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น79.68-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA